vs
Bluerock Homes Trust, Inc.（BHM）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Bluerock Homes Trust, Inc.的1.6倍（$30.3M vs $18.9M），Bluerock Homes Trust, Inc.净利率更高（-50.1% vs -221.3%，领先171.2%），REGENXBIO Inc.同比增速更快（43.0% vs 35.9%），Bluerock Homes Trust, Inc.自由现金流更多（$10.4M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 30.1%）
Bluerock Homes Trust, Inc.是一家总部位于美国的房地产投资信托企业，主要收购、持有并运营优质单户住宅租赁资产，面向美国高增长郊区市场的中等收入租户，聚焦人口基本面向好、租赁需求旺盛的区域布局。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BHM vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.6倍
$18.9M
营收增速更快
RGNX
高出7.1%
35.9%
净利率更高
BHM
高出171.2%
-221.3%
自由现金流更多
BHM
多$63.2M
$-52.8M
两年增速更快
RGNX
近两年复合增速
30.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.9M | $30.3M |
| 净利润 | $-9.5M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -48.8% | -190.0% |
| 净利率 | -50.1% | -221.3% |
| 营收同比 | 35.9% | 43.0% |
| 净利润同比 | -29.9% | -31.2% |
| 每股收益（稀释后） | $-0.75 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BHMRGNX
| Q4 25 | $18.9M | $30.3M | ||
| Q3 25 | $16.6M | $29.7M | ||
| Q2 25 | $16.8M | $21.4M | ||
| Q1 25 | $16.4M | $89.0M | ||
| Q4 24 | $13.9M | $21.2M | ||
| Q3 24 | $12.7M | $24.2M | ||
| Q2 24 | $12.5M | $22.3M | ||
| Q1 24 | $11.2M | $15.6M |
净利润BHMRGNX
| Q4 25 | $-9.5M | $-67.1M | ||
| Q3 25 | $-10.0M | $-61.9M | ||
| Q2 25 | $-5.8M | $-70.9M | ||
| Q1 25 | $-7.3M | $6.1M | ||
| Q4 24 | $-7.3M | $-51.2M | ||
| Q3 24 | $3.5M | $-59.6M | ||
| Q2 24 | $-5.2M | $-53.0M | ||
| Q1 24 | $-3.2M | $-63.3M |
毛利率BHMRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BHMRGNX
| Q4 25 | -48.8% | -190.0% | ||
| Q3 25 | -57.6% | -176.3% | ||
| Q2 25 | -30.9% | -296.3% | ||
| Q1 25 | -42.6% | 13.6% | ||
| Q4 24 | -52.8% | -242.1% | ||
| Q3 24 | 27.9% | -256.6% | ||
| Q2 24 | -41.3% | -251.3% | ||
| Q1 24 | -28.4% | -408.8% |
净利率BHMRGNX
| Q4 25 | -50.1% | -221.3% | ||
| Q3 25 | -60.0% | -208.3% | ||
| Q2 25 | -34.7% | -331.8% | ||
| Q1 25 | -44.7% | 6.8% | ||
| Q4 24 | -52.8% | -241.3% | ||
| Q3 24 | 27.9% | -246.3% | ||
| Q2 24 | -41.3% | -237.7% | ||
| Q1 24 | -28.4% | -405.4% |
每股收益（稀释后）BHMRGNX
| Q4 25 | $-0.75 | $-1.30 | ||
| Q3 25 | $-0.94 | $-1.20 | ||
| Q2 25 | $-0.66 | $-1.38 | ||
| Q1 25 | $-0.67 | $0.12 | ||
| Q4 24 | $-0.65 | $-0.99 | ||
| Q3 24 | $0.24 | $-1.17 | ||
| Q2 24 | $-0.42 | $-1.05 | ||
| Q1 24 | $-0.27 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $169.6M | $230.1M |
| 总债务越低越好 | $428.4M | — |
| 股东权益账面价值 | $128.7M | $102.7M |
| 总资产 | $1.2B | $453.0M |
| 负债/权益比越低杠杆越低 | 3.33× | — |
8季度趋势，按日历期对齐
现金及短期投资BHMRGNX
| Q4 25 | $169.6M | $230.1M | ||
| Q3 25 | $2.1M | $274.2M | ||
| Q2 25 | $4.2M | $323.3M | ||
| Q1 25 | $3.0M | $267.9M | ||
| Q4 24 | $115.2M | $234.7M | ||
| Q3 24 | $155.1M | $255.5M | ||
| Q2 24 | $116.0M | $290.4M | ||
| Q1 24 | $92.3M | $338.7M |
总债务BHMRGNX
| Q4 25 | $428.4M | — | ||
| Q3 25 | $415.9M | — | ||
| Q2 25 | $338.6M | — | ||
| Q1 25 | $336.5M | — | ||
| Q4 24 | $373.8M | — | ||
| Q3 24 | $122.5M | — | ||
| Q2 24 | $119.7M | — | ||
| Q1 24 | $120.2M | — |
股东权益BHMRGNX
| Q4 25 | $128.7M | $102.7M | ||
| Q3 25 | $131.7M | $161.5M | ||
| Q2 25 | $135.3M | $213.7M | ||
| Q1 25 | $137.1M | $274.2M | ||
| Q4 24 | $139.1M | $259.7M | ||
| Q3 24 | $142.9M | $301.4M | ||
| Q2 24 | $142.5M | $348.3M | ||
| Q1 24 | $144.5M | $390.7M |
总资产BHMRGNX
| Q4 25 | $1.2B | $453.0M | ||
| Q3 25 | $222.1M | $525.2M | ||
| Q2 25 | $220.3M | $581.0M | ||
| Q1 25 | $186.2M | $490.9M | ||
| Q4 24 | $967.0M | $466.0M | ||
| Q3 24 | $800.8M | $519.1M | ||
| Q2 24 | $756.2M | $569.4M | ||
| Q1 24 | $727.4M | $629.2M |
负债/权益比BHMRGNX
| Q4 25 | 3.33× | — | ||
| Q3 25 | 3.16× | — | ||
| Q2 25 | 2.50× | — | ||
| Q1 25 | 2.45× | — | ||
| Q4 24 | 2.69× | — | ||
| Q3 24 | 0.86× | — | ||
| Q2 24 | 0.84× | — | ||
| Q1 24 | 0.83× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $10.4M | $-52.8M |
| 自由现金流率自由现金流/营收 | 55.0% | -174.0% |
| 资本支出强度资本支出/营收 | 91.8% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $25.0M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BHMRGNX
| Q4 25 | $27.8M | $-52.3M | ||
| Q3 25 | $13.4M | $-56.0M | ||
| Q2 25 | $13.9M | $-49.3M | ||
| Q1 25 | $951.0K | $33.6M | ||
| Q4 24 | $9.1M | $-31.6M | ||
| Q3 24 | $1.7M | $-40.5M | ||
| Q2 24 | $1.3M | $-45.5M | ||
| Q1 24 | $1.1M | $-55.5M |
自由现金流BHMRGNX
| Q4 25 | $10.4M | $-52.8M | ||
| Q3 25 | $8.7M | $-56.5M | ||
| Q2 25 | $8.8M | $-49.7M | ||
| Q1 25 | $-2.9M | $32.6M | ||
| Q4 24 | $-253.0K | $-32.7M | ||
| Q3 24 | $-601.0K | $-40.9M | ||
| Q2 24 | $-654.0K | $-46.0M | ||
| Q1 24 | $-630.0K | $-56.0M |
自由现金流率BHMRGNX
| Q4 25 | 55.0% | -174.0% | ||
| Q3 25 | 52.4% | -189.9% | ||
| Q2 25 | 52.2% | -232.8% | ||
| Q1 25 | -17.6% | 36.6% | ||
| Q4 24 | -1.8% | -154.2% | ||
| Q3 24 | -4.7% | -168.9% | ||
| Q2 24 | -5.2% | -206.2% | ||
| Q1 24 | -5.6% | -358.5% |
资本支出强度BHMRGNX
| Q4 25 | 91.8% | 1.7% | ||
| Q3 25 | 28.5% | 1.7% | ||
| Q2 25 | 30.3% | 1.8% | ||
| Q1 25 | 23.4% | 1.2% | ||
| Q4 24 | 66.9% | 5.1% | ||
| Q3 24 | 18.0% | 1.3% | ||
| Q2 24 | 15.3% | 2.1% | ||
| Q1 24 | 15.5% | 3.6% |
现金转化率BHMRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BHM
| Residential Communities Segment | $11.4M | 61% |
| Scattered Single Family Homes Segment | $7.5M | 39% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
